SEC Comment Letter 0000000000-23-006791 to Aptose Biosciences Inc. (APTOF)
Aptose Biosciences Inc.
Date: June 26, 2023 · CIK: 0000882361 · Accession: 0000000000-23-006791
AI Filing Summary & Sentiment
File numbers found in text: 333-272752
Letter
United States securities and exchange commission logo June 26, 2023 William Rice Chief Executive Officer Aptose Biosciences Inc. 251 Consumers Road, Suite 1105 Toronto, Ontario, Canada M2J 4R3 Re:Aptose Biosciences Inc. Registration Statement on Form S-1 Filed June 20, 2023 File No. 333-272752 Dear William Rice: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dillon Hagius at 202-551-7967 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Daniel Miller
Show Raw Text
United States securities and exchange commission logo
June 26, 2023
William Rice
Chief Executive Officer
Aptose Biosciences Inc.
251 Consumers Road, Suite 1105
Toronto, Ontario, Canada M2J 4R3
Re:Aptose Biosciences Inc.
Registration Statement on Form S-1
Filed June 20, 2023
File No. 333-272752
Dear William Rice:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dillon Hagius at 202-551-7967 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Daniel Miller